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Abstract
Objective—Current cerebrospinal fluid (CSF) tests for sporadic Creutzfeldt-Jakob disease
(sCJD) are based on the detection of surrogate markers of neuronal damage such as CSF 14-3-3
which are not specific for sCJD. A number of prion protein conversion assays have been
developed, including real-time quaking induced conversion (RT-QuIC). The objective of this
study is to investigate whether CSF RT-QuIC analysis could be used as a diagnostic test in sCJD.
Methods—An exploratory study was undertaken which analysed 108 CSF samples from patients
with neuropathologically confirmed sCJD or from control patients. Of the 108 CSF samples 56
were from sCJD patients (30 female, 26 male, aged 31–84 years; 62.3 ± 13.5 years) and 52 were
from control patients (26 female, 26 male, aged 43–84 years; 67.8 ± 10.4 years). A confirmatory
group of 118 patients were subsequently examined which consisted of 67 cases of
neuropathologically confirmed sCJD (33 female, 34 male, aged 39–82 years; 67.5 ± 9.0 years) and
51 control cases (26 female, 25 male, aged 36–87 years; 63.5 ± 11.6 years).
Results—The exploratory study showed that RT-QuIC analysis had a sensitivity of 91% and a
specificity of 98% for the diagnosis of sCJD. These results were confirmed in the confirmatory
study which showed that CSF RT-QuIC analysis had a sensitivity and specificity of 87% and
100% respectively.
Interpretation—This study shows that CSF RT-QuIC analysis has the potential to be a more
specific diagnostic test for sCJD than current CSF tests.
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INTRODUCTION
Creutzfeldt-Jakob disease (CJD) belongs to a family of fatal neurodegenerative diseases
known as transmissible spongiform encephalopathies (TSEs) or prion diseases. The most
common form of CJD, known as sporadic CJD (sCJD), presents with a rapidly progressing
dementia, ataxia and myoclonus, and death typically occurs within 6 months.
Neuropathologically these diseases are characterised by the post-translational
conformational change of a normal cellular protein, called prion protein (PrPC) into a
disease-associated form, termed PrPSc. PrPSc is partially protease-resistant and can induce
PrPC to undergo a conformational change and produce more PrPSc in a self-propagating
manner by a seeded aggregation process. The PrPSc, thus produced, accumulates throughout
the brain and this is accompanied by spongiform change of the neuropil, neuronal loss and
degeneration.
Apart from brain biopsy, there is no disease-specific pre-mortem diagnostic test for sCJD.
Current clinical diagnostic criteria rely on clinical features and the results of investigations
such as EEG, brain MRI and the presence of 14-3-3 in the cerebrospinal fluid (CSF).1,2
Since its introduction into the diagnostic criteria for sCJD in 1998, the analysis of CSF for
14-3-3 has become a widely accepted investigation in patients with suspected sCJD.3–5 This
protein is released into the CSF as a result of acute neuronal damage and as such is a
surrogate marker for the degenerative changes associated with sCJD. Indeed, there have
been a number of concerns raised about the specificity of CSF 14-3-3.6,7
This has prompted the search for a more specific and disease-related pre-mortem diagnostic
test for sCJD. The ability of PrPSc to convert PrPC into aggregated protease-resistant
isoforms has been exploited using a variety of techniques such as protein misfolding cyclic
amplification (PMCA) and quaking induced conversion (QuIC) which mimic the PrPC to
PrPSc conversion process in an accelerated in vitro format. Using such techniques PrPSc has
been detected in the blood of pre-clinical scrapie-infected hamsters,8 in the CSF of hamsters
experimentally infected with scrapie9 and in sheep with clinical scrapie.10
A recent adaptation of QuIC (real-time QuIC) has been described which incorporates
thioflavin T (ThT) along with recombinant PrP in the reaction mixture. The ThT binds to the
aggregated recombinant PrP causing a change in the ThT emission spectrum that can be
monitored in real-time. Recent studies have shown that CSF samples from hamsters
inoculated with experimental scrapie and from patients with sCJD can be correctly identified
using real-time QuIC (RT-QuIC).9,11,12 We now describe the findings of a blinded
retrospective investigation into the value of RT-QuIC in the diagnosis of sCJD.
MATERIALS AND METHODS
Patients
The study included an exploratory group of 108 patients consisting of 56 cases of
neuropathologically confirmed sCJD14 (30 female, 26 male aged 31 – 84 years (mean 62.3 ±
13.5 years) at notification) and 52 control cases (26 female, 26 male aged 43 – 84 years
(mean 67.8 ± 10.4 years) at notification). A confirmatory group of 118 patients was
subsequently examined. This group consisted of 67 cases of neuropathologically confirmed
sCJD14 (33 female, 34 male aged 39 – 82 years (mean 67.5 ± 9.0 years) at notification) and
51 control cases (26 female, 25 male aged 36 – 87 years (mean 63.5 ± 11.6 years) at
notification). All the control cases consisted of patients who were initially suspected of
having sCJD but subsequently had either a pathologically proven alternative diagnosis or an
alternative clinical diagnosis provided by either the clinical team or by a member of the
NCJDRSU (Supplementary material Table 1). Of all the sCJD cases investigated 59 were
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homozygous for methionine at codon 129 of the PRNP gene, 25 were heterozygous for
methionine and valine and 20 were homozygous for valine.
CSF samples
Consecutive CSF samples which had greater than 0.5ml available for analysis were selected.
CSF samples were sent to the laboratory on dry ice and stored at −80°C prior to analysis.
Consent for research was obtained for each sample and ethical approval was given by the
MREC Scotland A (05/MRE00/67). All samples were analysed blinded to the final
diagnosis.
Sporadic CJD brain tissues
Brain tissue was provided by the MRC Brain Bank in the NCJDRSU from examples of each
of the six clinico-pathological sCJD subtypes as defined by the combination of their PRNP-
codon 129 genotype (MM, MV, VV) and their PrPres type (type 1 or 2) according to the
nomenclature of Parchi and Gambetti 14,15 as MM1, MM2-cortical subtype, MV1, MV2,
VV1 and VV2. All cases used had been thoroughly examined histologically and
biochemically and the diagnosis reached using internationally accepted criteria. In each case
grey matter enriched samples of ~100mg were taken from the frontal cortex for preparation
as seed material for RT-QuIC.
The amounts of brain homogenate introduced into the RT-QuIC assays were normalized
according to the titre of PrPres. Proteinase K (PK) digested (50μg/ml) samples of sCJD brain
homogenate were compared alongside dilutions of purified human recombinant PrP
(rHuPrP). The levels of PrPres per unit of brain extract were estimated by comparing the
densities of the single Western blot band corresponding to purified rHuPrP and the
combined densities of the three bands corresponding to the PrPres in the brain extracts. This
was used for calculation of serial dilutions of the brain homogenates to 100fg PrPres/2μl.
Aliquots of 10% w/v brain homogenate (BH) were thawed at room temperature freshly for
each RT-QuIC assay. The brain homogenates were diluted by serial 1:10 dilutions using N2
buffer (PBS containing 0.1% SDS and 1 × N2 supplement [Invitrogen]). A 10μl sample was
added to 90μl of N2 buffer, with vortex mixing between each serial dilutions (4x). Brain
was diluted so that a 2μl volume of the final dilution would contain 100fg PrPres. For sCJD
frontal cortex tissue samples the dilution of 100% brain tissue required for this varied from 5
× 10−6 to 7.5 × 10−5.
Control brain tissues
Frontal cortex tissue was also taken from two Alzheimer’s disease (AD) cases. These cases
were referred to the NCJDRSU as suspected cases of CJD, but were found to have
neuropathological evidence of AD at post-mortem and as such were used as negative
controls. In addition, two further negative controls from individuals without
neurodegenerative diseases were obtained from the MRC Sudden Death Brain and Tissue
Bank (Sudden Death (SD) controls). The AD and SD BHs were diluted 1×10−6 with N2
buffer. Ethical approval for the use of brain tissue from the MRC NCJDRSU Brain and
Tissue Bank was covered by Tayside B ethics committee 11/ES/0022 Edinburgh Brain
Bank/
Preparation of hamster recombinant PrP
Hamster recombinant PrPC (rPrPC), (residues 23–231; accession K02234) was prepared
according to the method of Wilham et. al.11 with minor modifications. The concentration of
rPrPC was determined by BCA reagent (Thermo Scientific) and adjusted to 0.2–0.5 mg/mL.
Aliquots were stored at −80°C until use. Purity of rPrPC was estimated at 99%, by SDS-
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PAGE and immunoblotting (data not shown). Human rPrP was investigated as a possible
substrate for RT-QuIC. However, despite having a shorter lag-phase, the RT-QuIC reactions
showed an increased number of spontaneous aggregations in the unseeded reactions and
non-CJD control brain homogenate seeded reactions. For this reason all subsequent
investigations used hamster rPrP.
Real-time QuIC Analysis
RT-QuIC buffer composition was as follows: 10mM phosphate buffer (pH 7.4), 170 mM
NaCl (total 300mM including phosphate buffer), 0.1 mg/mL rPrPC (Hamster 23–231), 10
μM Thioflavin-T (ThT), and 10 μM ethylenediaminetetraacetic acid tetrasodium salt
(EDTA). Reactions were prepared in a black 96-well, optical bottomed plate (Nalgene Nunc
International, #265301) in volumes of 98 μL for brain homogenate (BH) seeded reactions
and 85 μL for CSF seeded reactions. Correspondingly, 2 μL of diluted BH or 15 μL neat
CSF were added to the wells for a final reaction volume of 100 μL. Each sample was run in
quadruplicate, allowing 4 control samples [unseeded, SD BH, AD BH, sCJD-MM1 BH] and
20 CSF samples to be tested on one plate. The plates were sealed and incubated in a BMG
OPTIMA FLUOstar plate reader at 42°C for 90–120 h with intermittent shaking cycles:
double orbital with 1 minute shake (600rpm), 1 minute rest. ThT fluorescence measurements
(450nm excitation and 480nm emission) were taken every 15 minutes.
The plate reader measures ThT fluorescence in relative fluorescence units (rfu) with
saturation occurring at 65,000. The average fluorescence for each quadruplicate sample was
monitored against time. A baseline rfu of ~5,000 for CSF and unseeded reactions and
~8,000 for BH seeded reactions was to be expected for the initial readings. This difference
in baseline readings is probably due to the presence of a small amount of SDS (0.002%) in
the BH seeded reactions and its absence in the CSF and unseeded reactions. Following a lag
phase of ~10hrs for sCJD BH and >30hrs for sCJD CSF, positive samples displayed a rise in
rfu. By 90hrs the majority of the sCJD CSF seeded reactions had shown an increase in
fluorescence. A positive response was considered to have occurred if the average of the two
highest readings at 90 hours was 10,000 rfu or greater. A cut-off value of 10,000 rfu was
chosen based on the mean ± 3SD (5696 ± 1962) of the first 20 non-CJD CSF samples
analysed.
SDS-PAGE and immunoblotting
For SDS-PAGE analysis, BH and CSF seeded RT-QuIC products were incubated with 6ug/
mL proteinase K (PK) in the presence of 0.27% N-lauroylsarcosine sodium salt for 1 hr at
37°C followed by the addition of 2x SDS-PAGE sample buffer (containing 4M urea). CSF
seeded RT-QuIC products were diluted a further 6-fold with sample buffer. BH seeded RT-
QuIC products were not additionally diluted. PK digested samples were immunoblotted
using polyclonal anti-PrP antibody R20.
CSF 14-3-3 analysis
CSF 14-3-3 analysis was undertaken as previously described.16
PRNP codon 129 genotype and PrP isotyping
Prion protein isotyping was performed on all suspected cases of prion disease where frozen
brain tissue was received by the NCJDRSU as previously described.17 DNA was extracted
from brain using standard techniques and analysed using the Helsinki method.18
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Statistical analysis
The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV)
and efficiency of each marker were obtained. Statistical significance between groups was
assessed using two-tailed Mann-Whitney U-test using 3 replicates.
RESULTS
The kinetics of the RT-QuIC reactions seeded with sCJD, AD and SD BHs are shown in
Figure 1. The BHs from all six subtypes of sCJD show positive responses which start after a
lag phase of between 5 and 20 hours. This demonstrated that the hamster full-length rPrP
could act as a universal substrate for all subtypes of sCJD. From Figure 1 it appears that the
sCJD-MM2 (cortical subtype) and sCJD-VV1 BHs have longer lag phases than the other
sCJD subtypes, however this was not a consistent finding. Flat responses were seen with the
unseeded reactions and those reactions seeded with AD and SD BHs.
The RT-QuIC responses from reactions seeded with sCJD CSF samples show a similar
pattern to those obtained using sCJD BHs, although there is a greater lag phase of
approximately 30 hours and the maximal responses obtained are less (Figure 2).
Positive RT-QuIC responses are seen in reactions seeded with sCJD CSF samples from all
three genotypes of sCJD. There is marked variation in the rate of increase in the rfu signal
between the sCJD CSF samples investigated, however by 90 hours the RT-QuIC response
flattens out. The RT-QuIC responses at 90 hours for each CSF sample investigated in this
study are shown in Figure 3. There is no relationship between the PRNP codon 129 status of
the patient and the maximal rfu signal obtained by RT-QuIC analysis. In addition no
correlation was found between the age at onset of disease, disease duration, timing of
lumbar puncture and the final RT-QuIC response (r2 <0.05).
Using the criteria of 10,000 rfu at 90 hours to investigate the exploratory group of patients
we found that positive RT-QuIC responses were obtained in 51/56 CSF samples from sCJD
patients and in one patient from the control group. This gave a sensitivity and specificity of
91% and 98% respectively (Table 1). These results were replicated in the confirmatory
group of patients where positive RT-QuIC responses were found in 58/67 sCJD patients and
in none of the 51 control patients investigated. This resulted in a sensitivity and specificity
of 87% and 100% respectively.
The sensitivity of RT-QuIC was comparable to CSF 14-3-3 a marker that is currently used
for the investigation of patients with suspected sCJD (Table 1). Fourteen sCJD CSF samples
were negative for RT-QuIC and there was no difference between these patients and those
who where positive for RT-QuIC in terms of age at onset of disease, disease duration, timing
of CSF sampling or PRNP codon 129 genotype. All but two of these 14 sCJD patients were
positive for CSF 14-3-3 and one of the two remaining patients had triphasic waves on their
EEG that were typical for sCJD. The remaining patient did not show any changes on the
EEG or MRI that were typical for sCJD and a review of the neuropathology revealed
changes that were consistent with a variably protease-sensitive prionopathy. This patient
was homozygous for methionine at codon 129 of the PRNP gene; the brain showed
spongiform change in the cerebral cortex and contained microplaques and plaque-like PrP
deposits in the cerebellum, with plaque-like deposits in the cerebrum as recently described
by Zou et al.19 The PrP deposits in this case showed more sensitivity to proteinase K
digestion than those in sCJD (personal communication, James Ironside).
The specificity of RT-QuIC was substantially better than that of CSF 14-3-3 (Table 2). Only
one control patient gave a positive RT-QuIC response. This patient presented with
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progressive memory loss, developed gait impairment and became mute. The patient had a
positive CSF 14-3-3, the EEG showed non-specific changes and the MRI showed age-
related vascular changes and the presence of a bilateral subdural haematoma. A clinical
diagnosis of vascular dementia was made and after a disease duration of between 10–17
months the patient died. No post-mortem was performed. Further review of this patient’s
notes by two independent neurologists concluded that a diagnosis of sCJD could not be
excluded.
Because RT-QuIC uses an indirect measure (ThT binding) to assess rPrP aggregation state,
the products formed by RT-QuIC reactions were subjected to mild PK digestion and
Western blotting (Figure 4) to characterise the reaction product.
The gels were immunoblotted using R20, an antibody that binds to the C-terminus of the
PrP20, which is included in the protease resistant core of PrPSc. Fig 4A shows that the
products formed by RT-QuIC reactions seeded with sCJD BH contain a series of PK-
resistant bands, the most prominent of which are less than 20kDa, in addition to a band at
~28kDa. The <20kDa bands are specific to RT-QuIC reactions seeded with sCJD BH
whereas the ~28kDa band is found at variable intensity in all PK-treated RT-QuIC reaction
products and represents residual full length rPrP that escaped proteolysis. A total of 4.5ng of
untreated hamster rPrP was added to lane R, and, prior to PK digestion, the amount of
hamster rPrP in each of the RT-QuIC reaction mixtures loaded on the gel was 500ng. The
RT-QuIC reaction mixture seeded with MV1 sCJD BH had the largest amount of residual
undigested hamster rPrP, which was estimated to be 9ng, based on the comparison of the
band intensity to that of the untreated hamster rPrP (lane R). This means that <2% of the
total rPrP present in each RT-QuIC reaction remained undigested with ~98% of the hamster
rPrP having undergone at least partial PK digestion. Minor amounts of such residual full-
length ~28 kDa rPrP bands are often seen in QuIC reaction products independent of the
seeding status of the reactions10,21 and thus are inconsequential to the interpretation of the
results. The molecular weights of the smaller PK-digested bands are similar to those
previously reported for 263K scrapie seeded RT-QuIC and for 263K scrapie and sheep
scrapie QuIC reactions.10,11 The banding pattern is similar in all of the subtypes of sCJD,
although the intensity of the bands varies, with the MM2 and MV2 seeded reactions being
less intense. RT-QuIC reactions which were unseeded or seeded with AD or SD BHs did not
show any PK-digested bands in the <20kDa region. The products from RT-QuIC reactions
seeded with sCJD CSF samples were found to be similar to those found in the sCJD BH (Fig
4B). No such PK-digested bands were found in the reaction seeded with an AD CSF sample.
The RT-QuIC products from the reaction seeded with the control CSF sample which gave a
positive RT-QuIC response, also showed the presence of PK-digested bands with a similar
pattern and molecular weights to those found in sCJD BH and CSF samples.
DISCUSSION
The results from this small retrospective study show that RT-QuIC analysis of CSF samples
from patients with suspected sCJD has a sensitivity and specificity of 89% and 99%
respectively. This compares well with the results from Atarashi et al12 who reported a
sensitivity of 80% and a specificity of 100%. There was found to be a single control patient
who was unexpectedly positive by RT-QuIC. The electrophoretic pattern of the resultant
RT-QuIC reaction products showed the presence of PK-digested bands with a similar pattern
and molecular weights to those found in sCJD BH and CSF samples. Subsequent
examination of the clinical records of this patient suggested that it was not possible to
exclude a diagnosis of sCJD and as this patient died without a post-mortem a definitive
diagnosis cannot be made.
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The results from this study show that RT-QuIC has a comparable sensitivity to CSF 14-3-3
but is considerably more specific. There is no relationship between the RT-QuIC response
obtained in sCJD cases and any clinical feature such as age at onset of disease, disease
duration or timing of the lumbar puncture.
The products created from RT-QuIC reactions seeded with sCJD CSF samples contain
hamster rPrP that has been converted to a partially PK resistant form, and is reminiscent of
genuine disease associated PrP. It is partially protease resistant and present in N-terminally
truncated forms. In contrast, as noted above, the ~28 kDa band most likely represents a
small portion of the original full-length rPrP substrate that escaped exposure to PK, perhaps
due to splashing up on the vessel wall or seed-independent, amorphous aggregation during
the QuIC reaction (compare seeded and unseeded lanes in figure 4A). Variable amounts of
such full-length rPrP residues have been observed previously in PK-digested QuIC reaction
products without any correlation of the test sample to TSE.10,21 Although the nature of the
material present in CSF of CJD patients that triggers the RT-QuIC reaction is not known it
seems plausible that it is a disease-associated form of PrP and therefore specific to CJD.
This is in contrast to CSF 14-3-3 which is a neuronal protein released into the CSF as a
result of neuronal damage and is therefore a surrogate marker for CJD. We suggest that it is
this difference that accounts for the higher specificity seen with RT-QuIC when compared to
CSF 14-3-3.
The RT-QuIC products created from reactions seeded with sCJD BH or CSF samples show
similar PK-resistance and PrP fragmentation pattern on Western blotting, suggesting that the
ability to “seed” the RT-QuIC is similar in both BH and CSF samples from sCJD. It is not
known whether the RT-QuIC products created from these seeding reactions are associated
with infectivity. However, multiple intracerebral inoculations of hamster rPrP RT-QuIC
products seeded with hamster scrapie BH have not induced scrapie in hamsters (J. Wilham
and B. Caughey, unpublished data).
In conclusion, this study demonstrates that RT-QuIC analysis of CSF samples from patients
with suspected sCJD has the potential to be a more accurate pre-mortem diagnostic test for
sCJD than CSF 14-3-3, most probably because the analyte is a disease-specific rather than
surrogate marker. However, further studies are required to assess the sensitivity of CSF RT-
QuIC in each of the sCJD subgroups and to assess the complementary role that CSF 14-3-3
and RT-QuIC may have in the clinical diagnosis of sCJD. Further studies, such as eQuIC21
are being pursued to improve the sensitivity whilst maintaining the high degree of specificity
of RT-QuIC. In addition, greater numbers of CSF samples need to be investigated from
patients with the widest possible spectrum of TSEs to gain a better understanding of how
this potential new test can be used in both clinical and surveillance settings.
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Figure 1.
The RT-QuIC responses from reactions seeded with the equivalent of 100fg PrPres from
brain homogenates (BH) from six subtypes of sCJD, or an equivalent dilution (5 × 10−6) of
an AD BH and a normal/sudden death (SD) BH. An unseeded reaction is also shown. Each
point represents the mean of 4 replicate rfu readings.
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Figure 2.
The RT-QuIC responses from reactions seeded with 100fg of sCJD-MM BH, 15μl of CSF
from two sCJD-MM, two sCJD-MV and two sCJD-VV cases. The RT-QuIC responses from
the unseeded reaction and from reactions seeded with two CSF samples from AD patients,
one from a patient with Lewy body dementia and one from a patient with non-CJD, non-AD
dementia are also shown. Each point represents the mean of 4 replicate rfu readings.
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Figure 3.
Combined scatter and box and whisker plots of the CSF RT-QuIC rfu in control patients
(○), sCJD – MM genotype (◇), sCJD – MV genotype (□) and, sCJD – VV genotype (△).
Each point represents the average of the two highest rfu readings for each patient
investigated. Box and whisker plots show the 2nd, 25th, 75th and, 98th centiles.
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Figure 4.
SDS-PAGE and immunoblot of RT-QuIC products from reactions seeded with BHs from
patients with sCJD, AD or SD. The unseeded RT-QuIC reaction products (UnS), the
hamster rPrP (R) and the sCJD-MM1 BH seed are also shown. SDS-PAGE and immunoblot
of RT-QuIC products from reactions seeded with CSF samples from AD (2), sCJD (4, 8) or
from the control CSF sample that gave a positive reaction (6), the corresponding CSF
samples used for seeding the reactions are shown in 1,3,5,7. The western blot was
immunoblotted using R20 antibody. Protein molecular weight markers (MWM) are shown.
All lanes, except R, have been treated with 6μg/ml PK for 1 hour at 37°C. A total of 4.5ng
of untreated hamster rPrP was added to lane R. The amount of hamster rPrP in each of the
RT-QuIC reaction mixtures loaded on the gel was 500ng, prior to PK digestion,
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